madman
Super Moderator
GLP-1 receptor agonists are revolutionizing treatment for diabetes and obesity, but their impact on the gastrointestinal tract demands careful clinical attention. Dr. Peter Buch is joined by Dr. Michael Camilleri, Professor of Medicine at the Mayo Foundation for Medical Education and Research in Rochester, Minnesota, to discuss key findings on gastrointestinal side effects, procedural risks, and the impacts of GLP-1 receptor agonists on the fields of gastroenterology and hepatology.
GLP-1 Agonists and the GI Tract: Insights and Practical Guidance
By Dr. Peter Buck, GI Insights on ReachMD
Interview with Dr. Michael Camilleri, Mayo Foundation for Medical Education and Research
Minimizing GI Side Effects of GLP-1 Agonists
Gastrointestinal (GI) adverse effects such as nausea, vomiting, diarrhea, and constipation are the most common complications observed in patients starting GLP-1 receptor agonists for diabetes or obesity[1][2][3]. Dr. Camilleri emphasizes a key strategy:
Dose Titration Is Crucial:
Initiate GLP-1 agonists at low doses and escalate more gradually than standard FDA recommendations[4][5].
Slower dose increases can significantly reduce GI symptoms and improve patient adherence.
In clinical trials, all patients could reach the desired dose (e.g., liraglutide 3 mg/day) when escalation was tailored to their tolerance level.
Practical Tips:
Start at the lowest possible dose.
Increase doses at a pace guided by patient side effect tolerance, not calendar time.
Encourage small, frequent meals and slower eating.
GLP-1 Agonists and Risk of Pancreatitis
Pancreatitis risk remains an area of ongoing debate:
Animal Studies:
Results are conflicting, with some models showing a theoretical risk, but others finding no link[6].
FDA Adverse Event Reports:
Thousands of cases have been reported; however, many involve only elevated pancreatic enzymes, not proven acute pancreatitis[6][7].
Human Clinical Data:
Large systematic reviews and meta-analyses encompassing tens of thousands of patients across numerous randomized controlled trials have not found a significant increase in acute pancreatitis risk with GLP-1 agonists compared to placebo or other therapies[6][7][8][9][10].
Slight increases in serum amylase/lipase are common, but not generally associated with clinical pancreatitis.
Summary:
Current evidence does not support an increased risk of acute pancreatitis with GLP-1 agonist use in clinical practice[6][7][9].
Managing GLP-1s in Endoscopy: Minimizing Aspiration Risk
The approach to handling GLP-1s before endoscopic procedures has recently evolved:
Screen for Gastroparesis Symptoms:
Ask patients about nausea, vomiting, early satiety, or postprandial fullness.
For those with symptoms, consider stopping GLP-1s (for weekly injectables, stop 7 days prior; for dailies, stop 1-2 days prior)[11][12].
Routine Discontinuation Not Required for All:
Major GI societies now advise against universally stopping GLP-1s before endoscopy unless symptoms suggest delayed gastric emptying[12][13].
Recommended Precautions:
Advise a full liquid diet for at least 24 hours before procedure (consider 48 hours for colonoscopy prep)[12][14].
Ensure standard fasting (minimum 8 hours for solids).
Only use point-of-care ultrasound selectively in symptomatic patients due to limited access and practicality.
Guideline Highlights:
Recent multi-society guidance endorses an individualized approach based on symptoms and risk factors, rather than blanket medication holds[12][13][15].
GLP-1s and Colonoscopy: Adjusting Bowel Prep
GLP-1 agonists can increase the risk of inadequate bowel preparation due to their motility-slowing effects:
Research Findings:
GLP-1 users have higher rates of poor bowel cleansing, prompting more repeat procedures[14][16][17][18].
Best Practices:
Recommend a prolonged liquid diet (at least 24-48 hours) before prep begins.
Ensure diligent adherence to bowel prep instructions and emphasize the importance to patients.
Impact on Liver Disease and Fibrosis
Recent data highlight promising benefits for liver health:
Liver Enzyme Reduction:
GLP-1 agonists consistently lower ALT and AST in patients with metabolic-associated fatty liver disease (MASLD), formerly NAFLD/NASH[19][20][21].
Fibrosis Impact:
Multiple trials, including new phase 2 and 3 studies, show improvement (or slowed progression) of liver fibrosis with GLP-1 receptor agonist therapy[22][19][23][24][20][25][21].
Guideline Update:
The American Diabetes Association now recommends routine screening for MASLD in patients prescribed GLP-1s for type 2 diabetes or obesity[25].
Final Takeaways
Dr. Camilleri’s concluding message is that gastroenterologists and hepatologists should see obesity treatment—often via GLP-1 agonists—as central to managing a wide variety of GI and liver diseases, not just diabetes.
GLP-1s not only support glycemic control and weight loss, but may also help with liver inflammation, fibrosis reduction, and possibly improve broader GI health by addressing the root causes of many comorbid conditions.
Key Points in Practice:
Use slow dose titration to minimize GI side effects of GLP-1s.
No strong evidence currently links GLP-1s to increased acute pancreatitis risk.
Do not automatically stop GLP-1s before endoscopy—screen for symptoms and use diet and fasting interventions.
For colonoscopies, extend the pre-procedure liquid diet as needed and stress adherence to bowel prep.
Watch for new evidence and update protocols as multi-society guidelines evolve.
GLP-1 agonists are reshaping GI and metabolic care, offering specialists new tools to address not only diabetes and obesity but also broader liver and GI conditions in clinical practice[1][4][6][22][19][23][12][14][20][25].
Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks - PMC
GLP-1 diabetes and weight-loss drug side effects:
https://www.goodrx.com/classes/glp-1-agonists/glp-1-side-effects
GLP-1 Pipeline Update: November 2024 - Prime Therapeutics - Portal
https://diabetesjournals.org/care/a...rence-of-Gastrointestinal-Adverse-Events-Upon
Frontiers | Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2813598
Pancreatitis Risk Associated with GLP-1 Receptor Agonists, Considered as a Single Class, in a Comorbidity-Free Subgroup of Type 2 Diabetes Patients in the United States: A Propensity Score-Matched Analysis - PMC
https://www.sciencedirect.com/science/article/pii/S0168822724007162
Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials - PubMed
https://www.jwatch.org/na57481/2024/05/14/glp-1-agonists-and-retained-gastric-contents-endoscopy
Impact of glucagon-like peptide receptor agonists on endoscopy and its preoperative management: Guidelines, challenges, and future directions - PMC
Study Challenges Seven-Day Hold on GLP-1 Agonists Before Surgery
GLP-1 Drugs Linked to Poor Colonoscopy Prep
American Society of Anesthesiologists Consensus-Based Guidance on Preoperative Management of Patients (Adults and Children) on Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
Glucagon-like peptide-1 receptor agonists significantly affect the quality of bowel preparation for colonoscopy - PubMed
Effect of Glucagon-Like Peptide-1 Receptor Agonists on Bowel Preparation for Colonoscopy - PubMed
GLP-1 ozempic semaglutide Colonoscopy bowel prep
Glucagon-like peptide-1 receptor agonists improve metabolic dysfunction-associated steatotic liver disease outcomes - Scientific Reports
https://www.natap.org/2024/EASL/NEJMoa2401943.pdf
https://pubmed.ncbi.nlm.nih.gov/38856224/
https://pubmed.ncbi.nlm.nih.gov/38720191/
https://pubmed.ncbi.nlm.nih.gov/38555202/
https://www.sciencedirect.com/science/article/abs/pii/S175199182400069X
https://www.jwatch.org/na57953/2024/09/24/glp-1-receptor-agonists-patients-with-liver-disease-and
Last edited by a moderator:
